Every Form 4 that Alpha Tau Medical Ltd (DRTS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DRTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRTS filings page.
Alpha Tau Medical Ltd. (DRTS) reported that Chief Financial Officer Levy Raphi exercised derivative securities to acquire 2,871 Ordinary Shares at $2.98 per share on August 21, 2026, and on the same day sold 2,871 Ordinary Shares at $15.0028 per share pursuant to a Rule 10b5-1 trading plan.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported two transactions in Ordinary Shares of Alpha Tau Medical Ltd. On 2026-08-11, he acquired 17,730 Ordinary Shares through an exercise or conversion of a derivative security at $2.98 per share, then on the same date sold 17,730 Ordinary Shares at $14.0032 per share. These trades were made pursuant to a Rule 10b5-1 trading plan. The filing does not state his total shareholdings after these transactions.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported same-day share transactions involving the company’s Ordinary Shares. He exercised 2,270 shares at a price of $2.98 per share and sold 2,270 shares in an open-market sale at $14.0011 per share. Following these transactions, he directly held 90,180 Ordinary Shares.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy executed an exercise-and-sell transaction in company Ordinary Shares. He exercised 17,873 shares at $2.98 per share and then sold 17,873 shares in an open-market sale at an average price of $13.0027 per share on July 2, 2026.
Following these transactions, Levy directly holds 90,180 Ordinary Shares. The pattern shows option exercise to acquire shares and a same-day sale of an equivalent number of shares, while maintaining a substantial remaining equity position.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported an exercise-and-sale transaction in Ordinary Shares. Levy sold 2,127 shares in an open-market transaction at an average price of $13.0189 per share and reported direct ownership of 90,180 shares immediately afterward. The filing also shows a corresponding M-code transaction for 2,127 shares at $2.98 per share classified as a derivative exercise or conversion, indicating these shares were acquired through an option exercise before being sold.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold 20,000 Ordinary Shares in an open-market transaction. The shares were sold at an average price of $12.0022 per share. After this sale, Raphi directly holds 90,180 Ordinary Shares of Alpha Tau Medical.
Alpha Tau Medical Ltd. Chief Financial Officer Raphi Levy reported open-market sales of 20,000 Ordinary Shares on June 25, 2026. The shares were sold in two transactions at a price of about $11.0002 per share. These transactions reflect a net reduction in his directly held shares.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported selling a total of 17,500 Ordinary Shares in open-market transactions. The Form 4 shows two sales on June 23, 2026, at prices of $10.0004 and $9.47 per share. These are non-derivative transactions in the company’s common equity.
Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold shares in the company. On June 3, 2026, he completed two open-market sales totaling 32,500 Ordinary Shares of Alpha Tau Medical Ltd. at prices of $10.7571 and $10.9005 per share. These were reported as non-derivative transactions with direct ownership.